515 E. 88th Street, Suite 1L New York, NY 10128 specific study to dates—included 32 patients with confirmed VHL and evaluated the ability of pazopanib to shrink lesions associated with the disease. Of the 31 evaluable patients in the study, 18 exhibited stable disease, while 13 had confirmed responses. None had progressive disease. Dose reductions were required in 12 patients and 8 patients had adverse events requiring discontinuation of the treatment (4 due to transaminitis). These results suggest that pazopanib may be an alternative to surgical intervention in some VHL cases.16 References 1. Lara P, Bauer TM, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO- 202/KEYNOTE-037. J Clin Oncol. 35, 2017 (suppl; abstr 4515) 2. Choueiri TK, Larkin JMG, Oya M, et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol. 35, 2017 (suppl; abstr 4504). 3. Apolo AB, Mortazavi A, Stein MN. A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors. J Clin Oncol. 35, 2017 (suppl; abstr 4562). 4. Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 35, 2017 (suppl; abstr 4505). 5. Sheng X, Yan X, Chi BTZ, et al. A phase I clinical trial of CM082 (X- 82) in combination with everolimus for treatment of metastatic renal cell carcinoma. J Clin Oncol 35, 2017 (suppl; abstr 4575) 6. Chowdhury S, McDermott DF, Voss MH, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 35, 2017 (suppl; abstr 4506). 7. Lin J, Hoffman-Censits JH, Kelly WK, et al. An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer. J Clin Oncol. 35, 2017 (suppl; abstr e16058). 8 . Escudier BJ, Rini BI, Martini J-F, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.J Clin Oncol. 35, 2017 (suppl; abstr 4508). 9. Arafat W, Desotelle J, Rodems T, et al. Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial. J Clin Oncol. 35, 2017 (suppl; abstr 4579). 10. Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). J Clin Oncol. 35, 2017 (suppl; abstr 4507). 11. Welsh S, Fife K, Matakidou A, et al. A phase II clinical study evaluating the efficacy and safety of neoadjuvant and adjuvant sunitinib in previously untreated patients with metastatic renal cell carcinoma (mRCC)(NeoSun). J Clin Oncol. 35, 2017 (suppl; abstr e16087). 12. Shepherd STC, Hall P, Brown JE. Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma? J Clin Oncol. 35, 2017 (suppl; abstr e16061). 13. Tannir NM, Powles T, Escudier BJ, et al. Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 35, 2017 (suppl; abstr 4570). 14. Tannir NM, Camillo P, Gruenwald V, et al. Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis. J Clin Oncol.l 35, 2017 (suppl; abstr 4572). 15. Yip S, Wells C, Moreira RB, et al. Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol. 35, 2017 (suppl; abstr 4580). 16. Jonach E, Gombos D, Waguespack S, et al. Phase II study of pazopanib in patients with von Hippel-Lindau disease. J Clin Oncol. 35, 2017 (suppl; abstr 4516). 17. Pal SK, Geynisman DM, Ali SM, et al. Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset. J Clin Oncol. 35, 2017 (suppl; abstr 4517). KCJ (continued from page 55)
20291GA
To see the actual publication please follow the link above